Tag Archives: LIMR

Clinical Trial of the Week: Interventional study for patients diagnosed with moderate or severe peripheral artery disease

By Donna Loyle, communications specialist, LIMR The Shockwave Disrupt PAD III trial is underway at Bryn Mawr Hospital, with Sarang Mangalmurti, MD, (right) serving as principal investigator and Lynn Sher, MBA, as clinical research coordinator. Main Line Health has enrolled more … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Open office hours set by population health research team to help MLH clinicians with their research initiatives

MLH Clinicians: Are you interested in performing research studies to help improve the health of those in our community, but you’re unsure of how to get started or the next steps to take to advance your projects? The Main Line … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Screening study of patients with recurrent non-small cell lung cancer

By Donna Loyle, communications specialist, LIMR The Lung-MAP clinical trial is a master screening protocol for recurrent non-small cell lung cancer (NSCLC). The primary objective of this randomized phase II/III clinical study is to test patient specimens to determine eligibility … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Best read of the week

FDA Chief Calls For Stricter Scrutiny Of Electronic Health Records Kaiser Health News: Food and Drug Administration Commissioner Scott Gottlieb on Wednesday called for tighter scrutiny of electronic health records systems, which have prompted thousands of reports of patient injuries … Continue reading

Posted in Clinician News | Tagged | Leave a comment

LIMR Seminar: “How does a shark help with Parkinson’s disease?”

  By Donna Loyle, communications specialist, LIMR Michael A. Zasloff, MD, PhD, professor of surgery and pediatrics at Georgetown University Hospital, and scientific director of the MedStar-Georgetown Transplant Institute, will visit the Lankenau Institute of Medical Research on Thurs., April … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment study is testing for reduced recurrence of certain colorectal cancers

  By Donna Loyle, communications specialist, LIMR   Continuing with our focus on colorectal clinical trials during this, Colorectal Cancer Awareness Month, we highlight study #S0820. This double-blind, placebo-controlled trial seeks to determine if a treatment combination is effective in … Continue reading

Posted in Clinician News | Tagged | Leave a comment

LIMR investigators confirm potential medicinal benefit of a drug excipient

High doses of a substance long used in pharmaceutical manufacturing and previously believed to be benign appears to hold therapeutic value as an anti-inflammatory agent and to treat several disorders, including skin cancer, according to a newly published study from … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Interventional trial for patients diagnosed with resectable rectal cancer

By Donna Loyle, communications specialist, LIMR March is Colorectal Cancer Awareness Month, which makes this a great time to highlight the taTME clinical trial available at Lankenau Medical Center. This five-year, phase II, multicenter, single-arm surgical trial is for patients … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for patients with a certain type of colorectal cancer

By Donna Loyle, communications specialist, LIMR March is Colorectal Cancer Awareness Month, which makes this an ideal time to spotlight trial #S1613, ongoing at all Main Line Health acute care hospitals. This trial is for patients who’ve been diagnosed with … Continue reading

Posted in Clinician News | Tagged | Leave a comment

Clinical Trial of the Week: Treatment trial for certain patients diagnosed with stage 3 colon cancer

By Donna Loyle, communications specialist, LIMR Researchers are testing a combination of chemotherapy with or without the immunotherapy drug Tecentriq® (atezolizumab) in treating patients with stage 3 colon cancer and deficient DNA mismatch repair. There are two study arms to … Continue reading

Posted in Clinician News | Tagged | Leave a comment